Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Current Cardiovascular Imaging Reports
Published in: Current Cardiovascular Imaging Reports 1/2010

01-02-2010

Molecular Imaging of Thrombosis

Authors: Andrea J. Wiethoff, Marcus R. Makowski, Marcus Katoh, Elmar Spuentrup, René M. Botnar

Published in: Current Cardiovascular Imaging Reports | Issue 1/2010

Login to get access

Abstract

The diagnosis of thromboembolic diseases throughout the vascular system has been conducted with varying degrees of success by x-ray, ultrasound, CT, and MRI. Recently, a variety of potential molecular targets have been identified for early thrombus detection. This article describes these potential targets and the application of several imaging modalities currently being investigated to more accurately diagnose thrombosis and embolism.
Literature
1.
Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 1995, 92:657–671.PubMed
2.
Cutlip DE, Baim DS, Ho KK, et al.: Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001, 103:1967–1971.PubMed
3.
Honda Y, Fitzgerald PJ: Stent thrombosis: an issue revisited in a changing world. Circulation 2003, 108:2–5.CrossRefPubMed
4.
Ojio S, Takatsu H, Tanaka T, et al.: Considerable time from the onset of plaque rupture and/or thrombi until the onset of acute myocardial infarction in humans: coronary angiographic findings within 1 week before the onset of infarction. Circulation 2000, 102:2063–2069.PubMed
5.
Rittersma SZ, van der Wal AC, Koch KT, et al.: Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention. Circulation 2005, 111:1160–1165.CrossRefPubMed
6.
Libby P: Act local, act global: inflammation and the multiplicity of “vulnerable” coronary plaques. J Am Coll Cardiol 2005, 45:1600–1602.CrossRefPubMed
7.
Casscells W, Naghavi M, Willerson, JT: Vulnerable atherosclerotic plaque: a multifocal disease. Circulation 2003, 107:2072–2075.CrossRefPubMed
8.
Gardner C, Lee K: Embolic stroke: classification, risk factors, and clinical pearls. Applied Neurology 2006, 2:7.
9.
10.
Merli GJ: The treatment of venous thromboembolism. Am J Med 2008, 121.
11.
12.
13.
Pengo V, Lensing AW, Prins MH, et al.: Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004, 350:2257–2264.CrossRefPubMed
14.
Williamson TL, Kim NH, Rubin LJ: Chronic thromboembolic pulmonary hypertension. Prog Cardiovasc Dis 2002, 45:203–212.CrossRefPubMed
15.
Jamieson SW, Kapelanski DP, Sakakibara N, et al.: Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg 2003, 76:1457–1462; discussion 1462–1464.
16.
Sorensen HT, Horvath-Puho E, Pedersen L, et al.: Venous thromboembolism and subsequent hospitalization due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007, 370:773–779.
17.
Towbin A: The syndrome of latent cerebral sinus venous thrombosis: its frequency and relation to age and congestive heart failure. Stroke 1973, 4:419–430.PubMed
18.
Botnar RM, Perez AS, Witte S, et al.: In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004, 109: 2023–2029.CrossRefPubMed
19.
Botnar RM, Buecker A, Wiethoff AJ, et al.: In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 2004, 110:1463–1466.CrossRefPubMed
20.
Yu X, Song SK, Chen J, et al.: High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 2000, 44:867–872.CrossRefPubMed
21.
Flacke S, Fischer S, Scott MJ, et al.: Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 2001, 104:1280–1285.CrossRefPubMed
22.
Spuentrup E, Buecker A, Katoh M, et al.: Molecular magnetic resonance imaging of coronary thrombosis and pulmonary emboli with a novel fibrin-targeted contrast agent. Circulation 2005, 111:1377–1482.CrossRefPubMed
23.
Tung CH, Gerszten RE, Jaffer FA, et al.: A novel near-infrared fluorescence sensor for detection of thrombin activation in blood. Chembiochem 2002, 3:207–211.CrossRefPubMed
24.
Jaffer FA, Tung CH, Wykrzykowska JJ, et al.: Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fluorescent contrast agent that covalently links to thrombi. Circulation 2004, 110:170–176.CrossRefPubMed
25.
Tung CH, Quinti L, Jaffer FA, et al.: A branched fluorescent peptide probe for imaging of activated platelets. Mol Pharm 2005, 2:92–95.CrossRefPubMed
26.
Bates SM, Lister-James J, Jullian JA, et al.: Imaging characteristics of a novel technetium Tc-99m labeled platelet glycoprotein IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis or a history of deep vein thrombosis. Arch Intern Med 2003, 163:452–456.CrossRefPubMed
27.
Morris TA, Marsh JJ, Chiles PG, et al.: Single photon emission computed tomography of pulmonary emboli and venous thrombi using anti-D-dimer. Am J Respir Crit Care Med 2004, 169:987–993.CrossRefPubMed
28.
Sarda-Mantel L, Coutard M, Rouzet F, et al.: 99mTc-annexin-V functional imaging of luminal thrombus activity in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006, 26:2153–2159.CrossRefPubMed
29.
Lanza GM, Wallace KD, Scott MJ, et al.: A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996, 94:3334–3340.PubMed
30.
Schumann PA, Christiansen JP, Quigley RM, et al.: Targeted-microbubble binding selectively to GPIIb IIIa receptors of platelet thrombi. Invest Radiol 2002, 37:587–593.CrossRefPubMed
31.
Alonso A, Della Martina A, Stroick M, et al.: Molecular imaging of human thrombus with novel abciximab immunobubbles and ultrasound. Stroke 2007, 38:508–514.CrossRef
32.
Lindener JR: Molecular imaging of cardiovascular disease with contrast-enhanced ultrasonography. Nat Rev Cardiol 2009, 6:475–481.CrossRef
33.
Jaffer FA, Tung CH, Gerszten RE, et al.: In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler Thromb Vasc Biol 2002, 22:1929–1935.CrossRefPubMed
34.
Kim DE, Jaffer FA, Weissleder R, et al.: Near-infrared fluorescent imaging of cerebral thrombi and blood-brain barrier disruption in a mouse model of cerebral venous sinus thrombosis. J Cereb Blood Flow Metab 2005, 25:226–233.CrossRefPubMed
35.
• Jaffer FA, Libby P, Weissleder R: Molecular imaging of cardiovascular disease. Circulation 2007, 116:1052–1061. This is a comprehensive review of the recent state of cardiovascular molecular imaging.
36.
Moody AR, Murphy RE, Morgan PS, et al.: Characterization of complicated carotid plaque with magnetic resonance direct thrombus imaging in patients with cerebral ischemia. Circulation 2003, 107:3047–3052.CrossRefPubMed
37.
Murphy RE, Moody AR, Morgan PS, et al.: Prevalence of complicated carotid atheroma as detected by magnetic resonance direct thrombus imaging in patients with suspected carotid artery stenosis and previous acute cerebral ischemia. Circulation 2003, 107:3053–3058.CrossRefPubMed
38.
Moody AR: Direct imaging of deep-vein thrombosis with magnetic resonance imaging. Lancet 1997, 350:1073.
39.
van Beek EJ, Wild JM, Fink C, et al.: MRI for the diagnosis of pulmonary embolism. J Magn Reson Imaging 2003, 18:627–640.CrossRefPubMed
40.
Winter PM, Caruthers SD, Yu X, et al.: Improved molecular imaging contrast agent for detection of human thrombus. Magn Reson Med 2003, 50:411–416.CrossRefPubMed
41.
Morawski AM, Winter PM, Yu X, et al.: Quantitative “magnetic resonance immunohistochemistry” with ligand-targeted 19F nanoparticles. Magn Reson Med 2004, 52:1255–1262.CrossRefPubMed
42.
McCarthy JR, Patel P, Botnaru I, et al.: Multimodal nanoagents for the detection of intravascular thrombi. Bioconjug Chem 2009, 20:1251–1255.CrossRefPubMed
43.
Spuentrup E, Fausten B, Kinzel S, et al.: Molecular MR-imaging of atrial clots in a swine model. Circulation 2005, 112:396–399.CrossRefPubMed
44.
Stracke CP, Katoh M, Wiethoff AJ, et al.: Molecular MRI of cerebral venous sinus thrombosis using a new fibrin-specific MR contrast agent. Stroke 2007, 38:1476–1481.CrossRefPubMed
45.
Sirol M, Fuster V, Badimon JJ, et al.: Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005, 112:1594–1600.CrossRefPubMed
46.
Spuentrup E, Katoh M, Wiethoff AJ, et al.: Molecular coronary MR imaging of human thrombi using EP-2104R, a fibrin-targeted contrast agent: experimental study in a swine model. Rofo 2007, 179:1166–1173.PubMed
47.
Spuentrup E, Katoh M, Buecker A, et al.: Molecular MR imaging of human thrombi in a swine model of pulmonary embolism using a fibrin-specific contrast agent. Invest Radiol 2007, 42:86–95.CrossRef
48.
•• Vymazal J, Spuentrup E, Cardenas-Molina G, et al.: Thrombus imaging with fibrin-specific gadolinium-based MR contrast agent EP-2104R: results of a phase II clinical study of feasibility. Invest Radiol 2009, 44:697–704. This article reports the feasibility of the first molecularly targeted Gd MRI agent in humans.
49.
Spuentrup E, Botnar RM, Wiethoff AJ, et al.: MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol 2008, 18:1995–2005.CrossRefPubMed
50.
Johansson LO, Bjørnerud A, Ahlström HK, et al.: A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging 2001, 13:615–618.CrossRefPubMed
Metadata
Title
Molecular Imaging of Thrombosis
Authors
Andrea J. Wiethoff
Marcus R. Makowski
Marcus Katoh
Elmar Spuentrup
René M. Botnar
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Cardiovascular Imaging Reports / Issue 1/2010
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-009-9005-0

Other articles of this Issue 1/2010

Current Cardiovascular Imaging Reports 1/2010 Go to the issue

Clinical Trial Report

The ATHEROMA Study: Rapid Anti-inflammatory Effects of High-Dose Statin Pharmacotherapy Illuminated by Molecular MRI

OriginalPaper

Optical Molecular Imaging of Inflammation and Calcification in Atherosclerosis

OriginalPaper

Ultrasound Molecular Imaging of Cardiovascular Disease

OriginalPaper

Molecular and Microstructural Imaging of the Myocardium

OriginalPaper

Nanomedicine and Cardiovascular Disease

OriginalPaper

Molecular MRI of Atherosclerosis

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits